Header Logo

Connection

Frederick Raal to Adult

Back to Details
This is a "connection" page, showing publications Frederick Raal has written about Adult.
Frederick Raal
Connection Strength
2,969
Adult
  1. Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. Lancet Diabetes Endocrinol. 2025 Mar; 13(3):178-187.
    View in: PubMed
    Score: 0,111
  2. Ezetimibe in the management of homozygous familial hypercholesterolaemia. J Clin Lipidol. 2025 Mar-Apr; 19(2):320-326.
    View in: PubMed
    Score: 0,110
  3. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
    View in: PubMed
    Score: 0,107
  4. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
    View in: PubMed
    Score: 0,104
  5. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Circulation. 2024 01 30; 149(5):354-362.
    View in: PubMed
    Score: 0,102
  6. Evolocumab in patients with homozygous familial hypercholesterolemia in India. J Clin Lipidol. 2021 Nov-Dec; 15(6):814-821.
    View in: PubMed
    Score: 0,089
  7. Cascade Screening for Familial Hypercholesterolemia in South Africa: The Wits FIND-FH Program. Arterioscler Thromb Vasc Biol. 2020 11; 40(11):2747-2755.
    View in: PubMed
    Score: 0,082
  8. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020 08 20; 383(8):711-720.
    View in: PubMed
    Score: 0,082
  9. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020 04 16; 382(16):1520-1530.
    View in: PubMed
    Score: 0,079
  10. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia. J Am Coll Cardiol. 2020 02 18; 75(6):565-574.
    View in: PubMed
    Score: 0,079
  11. A pain in the neck. BMJ. 2019 Nov 21; 367:l6008.
    View in: PubMed
    Score: 0,078
  12. Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia: the ODYSSEY Open-Label Extension study. Cardiovasc J Afr. 2019 Sep/Oct 23; 30(5):279-284.
    View in: PubMed
    Score: 0,076
  13. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. Cardiovasc Drugs Ther. 2019 02; 33(1):69-76.
    View in: PubMed
    Score: 0,073
  14. Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: A retrospective review of 39 pregnancies. Atherosclerosis. 2018 10; 277:502-507.
    View in: PubMed
    Score: 0,072
  15. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. Eur Heart J. 2018 04 07; 39(14):1162-1168.
    View in: PubMed
    Score: 0,069
  16. Fibroblast growth factor-23 in patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2018 May - Jun; 12(3):767-772.
    View in: PubMed
    Score: 0,069
  17. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017 04; 5(4):280-290.
    View in: PubMed
    Score: 0,064
  18. Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis. 2016 May; 248:238-44.
    View in: PubMed
    Score: 0,060
  19. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):331-40.
    View in: PubMed
    Score: 0,054
  20. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24; 385(9965):341-50.
    View in: PubMed
    Score: 0,054
  21. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013 Nov 05; 128(19):2113-20.
    View in: PubMed
    Score: 0,050
  22. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013 Apr 24; 2(2):e000028.
    View in: PubMed
    Score: 0,049
  23. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012 Nov 13; 126(20):2408-17.
    View in: PubMed
    Score: 0,048
  24. High-dose statin therapy does not induce insulin resistance in patients with familial hypercholesterolemia. Metab Syndr Relat Disord. 2012 Oct; 10(5):351-7.
    View in: PubMed
    Score: 0,047
  25. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012 Aug; 223(2):262-8.
    View in: PubMed
    Score: 0,045
  26. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011 Nov 15; 124(20):2202-7.
    View in: PubMed
    Score: 0,044
  27. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,044
  28. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Mar 20; 375(9719):998-1006.
    View in: PubMed
    Score: 0,040
  29. Carotid intima-media thickness is a predictor of coronary artery disease in South African black patients. Cardiovasc J Afr. 2009 Jul-Aug; 20(4):237-9.
    View in: PubMed
    Score: 0,038
  30. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr. 2007 Sep-Oct; 18(5):325-9.
    View in: PubMed
    Score: 0,033
  31. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J. 2025 Mar 24; 46(12):1127-1140.
    View in: PubMed
    Score: 0,028
  32. Obesity phenotypes and dyslipidemia in adults from four African countries: An H3Africa AWI-Gen study. PLoS One. 2025; 20(1):e0316527.
    View in: PubMed
    Score: 0,028
  33. Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
    View in: PubMed
    Score: 0,026
  34. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 2003 Dec; 171(2):273-9.
    View in: PubMed
    Score: 0,026
  35. International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia. Nat Rev Cardiol. 2023 12; 20(12):845-869.
    View in: PubMed
    Score: 0,025
  36. Identifying the prevalence and correlates of multimorbidity in middle-aged men and women: a cross-sectional population-based study in four African countries. BMJ Open. 2023 03 14; 13(3):e067788.
    View in: PubMed
    Score: 0,024
  37. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia. J Clin Lipidol. 2022 Sep-Oct; 16(5):676-684.
    View in: PubMed
    Score: 0,023
  38. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022 02 19; 399(10326):719-728.
    View in: PubMed
    Score: 0,023
  39. Cerebrotendinous xanthomatosis without neurological involvement. J Intern Med. 2021 11; 290(5):1039-1047.
    View in: PubMed
    Score: 0,021
  40. Poor cardiovascular health is associated with subclinical atherosclerosis in apparently healthy sub-Saharan African populations: an H3Africa AWI-Gen study. BMC Med. 2021 02 10; 19(1):30.
    View in: PubMed
    Score: 0,021
  41. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Jun; 150(2):421-8.
    View in: PubMed
    Score: 0,020
  42. Cryptogenic Cushing Syndrome Due to a White Lie. Clin Chem. 2020 05 01; 66(5):658-663.
    View in: PubMed
    Score: 0,020
  43. A patient requiring 1,000 units of insulin per day! S Afr Med J. 2000 Apr; 90(4):357-8.
    View in: PubMed
    Score: 0,020
  44. Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. Am J Cardiol. 1999 Dec 01; 84(11):1344-6, A7.
    View in: PubMed
    Score: 0,019
  45. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,019
  46. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. J Intern Med. 1999 Jul; 246(1):75-80.
    View in: PubMed
    Score: 0,019
  47. Low-density lipoprotein cholesterol bulk is the pivotal determinant of atherosclerosis in familial hypercholesterolemia. Am J Cardiol. 1999 May 01; 83(9):1330-3.
    View in: PubMed
    Score: 0,019
  48. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 03 15; 19(1):61.
    View in: PubMed
    Score: 0,018
  49. Management of low-density lipoprotein cholesterol levels in South Africa: the International ChoLesterol management Practice Study (ICLPS). Cardiovasc J Afr. 2019 Jan/Feb 23; 30(1):15-23.
    View in: PubMed
    Score: 0,018
  50. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):592-598.
    View in: PubMed
    Score: 0,017
  51. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis. 1997 Dec; 135(2):249-56.
    View in: PubMed
    Score: 0,017
  52. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017 Nov - Dec; 11(6):1448-1457.
    View in: PubMed
    Score: 0,017
  53. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis. Eur J Prev Cardiol. 2017 11; 24(17):1843-1850.
    View in: PubMed
    Score: 0,017
  54. A double mutant LDL receptor allele in a cypriot family with heterozygous familial hypercholesterolemia. Hum Genet. 1997 Jul; 100(1):101-3.
    View in: PubMed
    Score: 0,016
  55. CpG hotspot mutations at the LDL receptor locus are a frequent cause of familial hypercholesterolaemia among South African Indians. Clin Genet. 1997 Jun; 51(6):394-8.
    View in: PubMed
    Score: 0,016
  56. Plasma fatty acid levels in South African interethnic male high school pupils at different ultimate risks of coronary heart disease. Clin Chim Acta. 1997 Feb 03; 258(1):31-46.
    View in: PubMed
    Score: 0,016
  57. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016 Oct; 30(5):473-483.
    View in: PubMed
    Score: 0,016
  58. Comprehensive management of non-insulin-dependent diabetes mellitus. A diabetes clinic revisited. S Afr Med J. 1996 Aug; 86(8 Suppl):1007-8, 1013.
    View in: PubMed
    Score: 0,015
  59. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report. Arterioscler Thromb Vasc Biol. 2016 08; 36(8):1647-50.
    View in: PubMed
    Score: 0,015
  60. Suboptimal Control of Lipid Levels: Results from 29 Countries Participating in the Centralized Pan-Regional Surveys on the Undertreatment of Hypercholesterolaemia (CEPHEUS). J Atheroscler Thromb. 2016 May 02; 23(5):567-87.
    View in: PubMed
    Score: 0,015
  61. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015 Sep 21; 36(36):2425-37.
    View in: PubMed
    Score: 0,014
  62. Susceptibility of low density lipoprotein to oxidation in familial hypercholesterolaemia. Atherosclerosis. 1995 May; 115(1):9-15.
    View in: PubMed
    Score: 0,014
  63. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015 Mar; 35(3):689-99.
    View in: PubMed
    Score: 0,014
  64. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015 Mar-Apr; 9(2):201-9.
    View in: PubMed
    Score: 0,014
  65. Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr. 1994 Oct; 60(4):579-85.
    View in: PubMed
    Score: 0,014
  66. Lack of effect of high dose vitamin E on xanthoma regression in homozygous familial hypercholesterolaemia. Atherosclerosis. 1994 Jun; 107(2):213-9.
    View in: PubMed
    Score: 0,013
  67. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015 Jul; 22(7):849-54.
    View in: PubMed
    Score: 0,013
  68. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014 Mar-Apr; 8(2):148-72.
    View in: PubMed
    Score: 0,013
  69. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
    View in: PubMed
    Score: 0,013
  70. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec; 34(45):3478-90a.
    View in: PubMed
    Score: 0,013
  71. The age of onset and sex distribution of insulin-dependent diabetes mellitus in Africans in South Africa. Postgrad Med J. 1993 Jul; 69(813):552-6.
    View in: PubMed
    Score: 0,012
  72. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,012
  73. The relationship between the development and progression of microalbuminuria and arterial blood pressure in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract. 1992 Jun; 16(3):221-7.
    View in: PubMed
    Score: 0,012
  74. Fat, protein and carbohydrate content of diets of white insulin-dependent diabetic adolescents and young adults. S Afr Med J. 1992 Apr 18; 81(8):399-402.
    View in: PubMed
    Score: 0,011
  75. Adiponectin and atherosclerosis risk factors in African hemodialysis patients: a population at low risk for atherosclerotic cardiovascular disease. Hemodial Int. 2012 Jan; 16(1):59-68.
    View in: PubMed
    Score: 0,011
  76. Comparison between surrogate indices of insulin sensitivity and resistance, and the hyperinsulinaemic euglycaemic glucose clamp in urban South African blacks with and without coronary artery disease. Diab Vasc Dis Res. 2010 Apr; 7(2):151-7.
    View in: PubMed
    Score: 0,010
  77. Leptin, adiponectin, and high-sensitivity C-reactive protein in relation to the metabolic syndrome in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord. 2009 Jun; 7(3):243-8.
    View in: PubMed
    Score: 0,009
  78. Postprandial hyperglycemia in urban South African blacks with and without coronary artery disease. Metab Syndr Relat Disord. 2009 Feb; 7(1):23-9.
    View in: PubMed
    Score: 0,009
  79. Haematological abnormalities in the acquired immunodeficiency syndrome. S Afr Med J. 1988 Aug 20; 74(4):157-60.
    View in: PubMed
    Score: 0,009
  80. Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM. 2008 Feb; 101(2):111-9.
    View in: PubMed
    Score: 0,009
  81. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008 Mar; 197(1):400-6.
    View in: PubMed
    Score: 0,008
  82. Autosomal recessive hypercholesterolaemia: discrimination of ARH protein and LDLR function in the homozygous FH phenotype. Clin Chim Acta. 2007 Mar; 378(1-2):33-7.
    View in: PubMed
    Score: 0,008
  83. High-dose atorvastatin therapy is required for significant improvement of endothelial function in heterozygous familial hypercholesterolaemic patients. Cardiovasc J S Afr. 2004 Mar-Apr; 15(2):70-5.
    View in: PubMed
    Score: 0,007
  84. Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1. Transplantation. 2002 Feb 27; 73(4):587-90.
    View in: PubMed
    Score: 0,006
  85. Quantity versus quality of LDL cholesterol in patients with familial hypercholesterolemia--which is more important? Clin Chim Acta. 2001 Dec; 314(1-2):167-73.
    View in: PubMed
    Score: 0,006
  86. Recent origin and spread of a common Lithuanian mutation, G197del LDLR, causing familial hypercholesterolemia: positive selection is not always necessary to account for disease incidence among Ashkenazi Jews. Am J Hum Genet. 2001 May; 68(5):1172-88.
    View in: PubMed
    Score: 0,005
  87. Cell adhesion molecules - can they be used to predict coronary artery disease in patients with familial hypercholesterolaemia? Clin Chim Acta. 2000 Mar; 293(1-2):105-13.
    View in: PubMed
    Score: 0,005
  88. Auto-antibodies against oxidized LDL as a marker of coronary artery disease in patients with familial hypercholesterolaemia. Ann Clin Biochem. 2000 Mar; 37 ( Pt 2):174-8.
    View in: PubMed
    Score: 0,005
  89. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000 Feb; 20(2):522-8.
    View in: PubMed
    Score: 0,005
  90. Circulating endothelium-related adhesion molecules in black South African patients with Graves' disease. Endocrine. 2000 Feb; 12(1):21-3.
    View in: PubMed
    Score: 0,005
  91. Insulin receptor substrate-1 gene variants in lipoatrophic diabetes mellitus and non-insulin-dependent diabetes mellitus: a study of South African black and white subjects. Hum Genet. 1997 Nov; 101(1):118-9.
    View in: PubMed
    Score: 0,004
  92. Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy. Osteoporos Int. 1997; 7(4):376-89.
    View in: PubMed
    Score: 0,004
  93. Microalbuminuria is not associated with cardiovascular disease in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 1995 Mar; 113(2):289-92.
    View in: PubMed
    Score: 0,003
  94. Selected risk factors for coronary heart disease in male scholars from the major South African population groups. S Afr Med J. 1993 Dec; 83(12):891-7.
    View in: PubMed
    Score: 0,003
  95. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993 Jul; 13(7):1076-81.
    View in: PubMed
    Score: 0,003
  96. Relationship between plasma insulin and blood pressure in South African black women in Johannesburg. Diabetes Care. 1992 Apr; 15(4):556-8.
    View in: PubMed
    Score: 0,003
  97. Insulin-receptor activity in nondiabetic and diabetic urbanized South African black women. Diabetes Care. 1992 Feb; 15(2):277-81.
    View in: PubMed
    Score: 0,003
  98. Cerebral phaeohyphomycosis caused by Xylohypha bantiana. Eur J Clin Microbiol Infect Dis. 1989 Nov; 8(11):984-8.
    View in: PubMed
    Score: 0,002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.